s
s
s
Develop highly selective and sensitive PK and ADA assays for infliximab (Remicade) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Infliximab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Infliximab Inhibitory Type 1 |
HCA212 |
AbD17837 |
Fab-V5Sx21 |
0.9 |
PK bridging ELISA |
|
HCA213 |
AbD17841_hIgG1 |
hIgG1 HRP |
1.8 |
PK bridging ELISA ADA control |
||
HCA233 |
AbD20436_hIgG1 |
hIgG1 |
0.12 |
PK bridging ELISA ADA control |
||
HCA234 |
AbD20436 |
Fab-FH2 |
0.12 |
PK bridging ELISA |
||
Infliximab & Infliximab-TNFα Non-Inhibitory Type 2 |
HCA214 |
AbD19376 |
Fab-FH2 |
0.7 |
PK bridging ELISA |
|
HCA215 |
AbD19370_hIgG1 |
hIgG1 |
1.4 |
PK bridging ELISA |
||
HCA216 |
AbD19376_hIgG1 |
hIgG1 HRP |
0.7 |
PK bridging ELISA |
||
Infliximab / TNFα Complex Specific Type 3 |
TZA009 |
AbD18391ad |
Fab-F-Spy2-H |
16
|
PK ELISA antigen capture format |
|
TZA009P |
AbD18391pap |
Fab2-FH-X22-HRP |
16
|
PK ELISA antigen capture format |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody, V5- and StrepX-StrepX- tags
2 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Type 1 anti-infliximab antibodies inhibit the binding of the drug infliximab to its target, tumor necrosis factor alpha, TNFα. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
Type 2 anti-infliximab antibodies bind to the infliximab idiotope, but do not inhibit the binding of infliximab to TNFα. They are ideal for development of a PK bridging ELISA to measure total drug - free, partially bound and fully bound.
The Type 3 antibodies specifically recognize the drug-target complex, detecting infliximab only when it is bound to TNFα. They are suitable as a detection antibody in a PK antigen capture assay.
Fig. 1. Infliximab PK bridging ELISA using antibodies HCA212 and HCA213P.
Schematic image of PK bridging ELISA detecting free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 2. Infliximab PK ELISA bridging format using antibodies HCA214 and HCA216P.
Schematic image of PK bridging ELISA detecting total drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
Fig. 3. Infliximab PK antigen capture ELISA using TZA009P.
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.
Fig. 4. ADA bridging ELISA using antibody HCA213.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.